Gencurix Receives Australian Government Approval for Droplex POLE Mutation Test
SEOUL, South Korea, Oct. 12, 2023 /PRNewswire/ — Gencurix, a cancer molecular diagnostics company, has obtained approval from the Australian Government (The Department of Health and Aged Care, Therapeutic Goods Administration) for its Droplex POLE Mutation Test targeting endometrial cancer mutations. This test employs Droplet Digital PCP (ddPCR) technology to analyze POLE gene mutations in […]